Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan

BACKGROUND: Until five years ago, the metastatic hormone-sensitive prostate cancer (mHSPC) treatment landscape was dominated by the use of androgen deprivation therapy (ADT) alone. However, novel hormonal agents (NHAs) and chemotherapy are now approved for male patients with mHSPC. This study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Leith, Andrea, Ribbands, Amanda, Kim, Jeri, Clayton, Emily, Gillespie-Akar, Liane, Yang, Lingfeng, Ghate, Sameer R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915525/
https://www.ncbi.nlm.nih.gov/pubmed/35277153
http://dx.doi.org/10.1186/s12894-022-00979-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915525/
https://www.ncbi.nlm.nih.gov/pubmed/35277153
http://dx.doi.org/10.1186/s12894-022-00979-9

Ejemplares similares